Gastroparesis Drugs Market Size

Gastroparesis Drugs Market size was valued at USD 5.9 billion in 2023 and is growing at a CAGR of 5% between 2024 and 2032, driven by factors such increased prevalence of diabetes worldwide due to rapid urbanization, lifestyles, and rising rates of regular alcohol and tobacco consumption.

For instance, as per the article published by Multidisciplinary Digital Publishing Institute (MDPI) in February 2024, it was found that approximately 9.3% of individuals with diabetes may experience the onset of gastroparesis during their illness. This risk appears to be heightened in individuals with long-standing type 1 diabetes or type 2 diabetes lasting ten years or more. Thus, the rapid increase in the prevalence of diabetes globally is expected to increase the incidence of diabetic gastroparesis that propel the demand for gastroparesis drugs, thereby boosting the growth of the market. Furthermore, the introduction of innovative drugs, by the manufacturers, aimed at symptom management, particularly for nausea and vomiting, is an important driving factor.

Gastroparesis means stomach paralysis - it is a condition affecting the nerves and muscles in the stomach. It interferes with the muscle activity (peristalsis) that moves food through the stomach and into the small intestine. Gastroparesis drugs are medications used to manage the symptoms of gastroparesis; a condition characterized by delayed emptying of the stomach. These medications aim to improve gastric motility and alleviate symptoms such as nausea, vomiting, bloating, and abdominal pain.